{"schema_version":"1.0","type":"article","title":"全網最全的「抗憂鬱新藥」最新進展盤點","url":"https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline.md","lang":"zh-Hant","date":"2026-05-15","publish_at":"2026-05-15T10:30:00+08:00","updated_at":"2026-05-15","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","BD","GLP-1","CNS","FDA","生技投資"],"summary":"【精神科藥物終於走出單胺時代？】📌 憂鬱症從來不是一個小市場。依 WHO 統計，全球約有 2.8 億人受到憂鬱症影響；若加上不同國家、不同診斷口徑下的未診斷與亞臨床族群，實際醫療負擔只會更高。這不是一","key_points":[],"facts":[],"sections":["01｜監管端：Caplyta、Ketamine、居家神經調控，三條路線同時推進","02｜快速起效：Psychedelic-like 藥物正在逼近主流精神醫學","03｜產後憂鬱：從靜脈輸注到口服與新機制","04｜憂鬱症不是只有情緒低落：睡眠、疲勞、嗜睡正在變成新戰場","05｜GLP-1 / GIP 進入憂鬱症：代謝藥的精神科羅生門","06｜精準精神醫學：憂鬱症終於開始有 biomarker 了？","07｜NK1、GABA、Glutamate：老標靶不一定死，只是需要新設計","08｜台灣「抗憂鬱藥」，也要看 CNS 平台能力"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Depressive disorder (depression","source":"","date":"","url":""},{"title":"WHO fact sheet on depression, providing information on prevalence, symptoms, prevention and contributing factors, diagnosis and treatment, and WHO's work in the area.","source":"","date":"","url":""},{"title":"www.who.int","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder","source":"","date":"","url":""},{"title":"CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled data from two Phase 3 studies 65% of patients reached remission with CAPLYTA®, with 43% achieving sustained","source":"","date":"","url":""},{"title":"www.jnj.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression","source":"","date":"","url":""},{"title":"This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of...","source":"","date":"","url":""},{"title":"www.prnewswire.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Premarket Approval (PMA","source":"","date":"","url":""},{"title":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm","source":"","date":"","url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm"},{"title":"www.accessdata.fda.gov","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Compass Pathways - Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression","source":"","date":"","url":""},{"title":"Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has historically been extremely difficult to achieve in TRD COMP360 is the first classic psychede","source":"","date":"","url":""},{"title":"ir.compasspathways.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：全網最全的「抗憂鬱新藥」最新進展盤點","url":"https://drugnews.com.tw/assets/articles/antidepressant-new-drugs-pipeline/dcard-01.webp"},{"alt":"Dcard 原圖：全網最全的「抗憂鬱新藥」最新進展盤點","url":"https://drugnews.com.tw/assets/articles/antidepressant-new-drugs-pipeline/dcard-02.png"},{"alt":"Dcard 原圖：全網最全的「抗憂鬱新藥」最新進展盤點","url":"https://drugnews.com.tw/assets/articles/antidepressant-new-drugs-pipeline/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/antidepressant-new-drugs-pipeline/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-15）。全網最全的「抗憂鬱新藥」最新進展盤點。https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-15-antidepressant-new-drugs-pipeline-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}